Femasys Announces Infertility Clinic Customers from Coast to Coast
Femasys Inc. (Nasdaq: FEMY) has announced the onboarding of its first infertility medical clinic customers to offer FemaSeed treatment in California and Florida. FemaSeed is a unique form of artificial insemination that delivers sperm directly into the fallopian tube, aiming to enhance natural fertilization. It's positioned as a cost-effective and safe first-line treatment option compared to IVF and ICSI.
Reproductive Fertility Center in Los Angeles and Palm Beach Fertility Center in Boca Raton are the first clinics to offer FemaSeed. Both clinics expressed enthusiasm about providing this new option to patients, citing its potential benefits over traditional IUI and its affordability. Femasys anticipates broader acceptance of FemaSeed as its benefits become more widely recognized in the medical community.
Femasys Inc. (Nasdaq: FEMY) ha annunciato l'inserimento dei suoi primi clienti di cliniche mediche per l'infertilità per offrire il trattamento FemaSeed in California e Florida. FemaSeed è una forma unica di inseminazione artificiale che introduce direttamente lo spermatozoo nella tuba di Falloppio, con l’obiettivo di migliorare la fertilizzazione naturale. È posizionato come un opzione di trattamento iniziale sicura e conveniente rispetto alla FIV e all'ICSI.
Il Reproductive Fertility Center di Los Angeles e il Palm Beach Fertility Center di Boca Raton sono le prime cliniche a offrire FemaSeed. Entrambe le cliniche hanno espresso entusiasmo nel fornire questa nuova opzione ai pazienti, citando i suoi potenziali vantaggi rispetto all'IUI tradizionale e la sua accessibilità. Femasys prevede una maggiore accettazione di FemaSeed man mano che i suoi benefici diventano più ampiamente riconosciuti nella comunità medica.
Femasys Inc. (Nasdaq: FEMY) ha anunciado la incorporación de sus primeras clínicas médicas de infertilidad como clientes para ofrecer el tratamiento FemaSeed en California y Florida. FemaSeed es una forma única de inseminación artificial que entrega esperma directamente a la trompa de Falopio, con el objetivo de mejorar la fertilización natural. Se posiciona como una opción de tratamiento inicial económica y segura en comparación con la FIV y el ICSI.
El Reproductive Fertility Center en Los Ángeles y el Palm Beach Fertility Center en Boca Ratón son las primeras clínicas en ofrecer FemaSeed. Ambas clínicas expresaron entusiasmo por proporcionar esta nueva opción a los pacientes, citando sus posibles beneficios sobre la IUI tradicional y su asequibilidad. Femasys anticipa una mayor aceptación de FemaSeed a medida que sus beneficios sean más reconocidos en la comunidad médica.
Femasys Inc. (Nasdaq: FEMY)는 캘리포니아와 플로리다에서 FemaSeed 치료를 제공하기 위해 첫 번째 불임 의료 클리닉 고객을 온보딩했다고 발표했습니다. FemaSeed는 정자를 직접 난관에 주입하는 독특한 형태의 인공 수정으로, 자연 수정 과정을 향상시키는 것을 목표로 하고 있습니다.IVF와 ICSI에 비해 비용 효율적이고 안전한 1차 치료 옵션으로 자리잡고 있습니다.
로스앤젤레스의 Reproductive Fertility Center와 보카 레이턴의 Palm Beach Fertility Center가 FemaSeed를 제공하는 첫 번째 클리닉입니다. 두 클리닉 모두 환자들에게 이 새로운 옵션을 제공하게 되어 열정을 표하며, 전통적인 IUI에 비해 그 이점과 경제성을 언급했습니다. Femasys는 FemaSeed의 이점이 의료 커뮤니티에서 더 널리 인식됨에 따라 그 수용이 확대될 것으로 기대하고 있습니다.
Femasys Inc. (Nasdaq: FEMY) a annoncé l'intégration de ses premières cliniques médicales spécialisées en infertilité comme clients pour offrir le traitement FemaSeed en Californie et en Floride. FemaSeed est une forme unique d'insémination artificielle qui délivre des spermatozoïdes directement dans la trompe de Fallope, visant à améliorer la fécondation naturelle. Il est présenté comme une option de traitement primaire économique et sûre par rapport à la FIV et à l'ICSI.
Le Reproductive Fertility Center à Los Angeles et le Palm Beach Fertility Center à Boca Raton sont les premières cliniques à offrir le FemaSeed. Les deux cliniques ont exprimé leur enthousiasme à l'idée de fournir cette nouvelle option aux patients, citant ses avantages potentiels par rapport à l'IUI traditionnelle ainsi que son accessibilité financière. Femasys anticipe une acceptation plus large du FemaSeed à mesure que ses avantages deviennent plus largement reconnus dans la communauté médicale.
Femasys Inc. (Nasdaq: FEMY) hat die Einbeziehung seiner ersten Kunden von Fertilitätsmedizinischen Kliniken angekündigt, um die FemaSeed-Behandlung in Kalifornien und Florida anzubieten. FemaSeed ist eine einzigartige Form der künstlichen Befruchtung, die Spermien direkt in die Eileiter einführt, um die natürliche Befruchtung zu fördern. Es wird als kosteneffiziente und sichere Erstbehandlungsoption im Vergleich zu IVF und ICSI positioniert.
Das Reproductive Fertility Center in Los Angeles und das Palm Beach Fertility Center in Boca Raton sind die ersten Kliniken, die FemaSeed anbieten. Beide Kliniken haben ihre Begeisterung zum Ausdruck gebracht, diese neue Option den Patienten anzubieten, wobei sie die potenziellen Vorteile im Vergleich zu herkömmlichem IUI und die Erschwinglichkeit hervorhoben. Femasys erwartet eine breitere Akzeptanz von FemaSeed, da die Vorteile in der medizinischen Gemeinschaft immer mehr anerkannt werden.
- Expansion of FemaSeed availability through partnerships with infertility centers across the U.S.
- FemaSeed positioned as a cost-effective alternative to more expensive fertility treatments like IVF and ICSI
- Positive feedback from partnering clinics, indicating potential for market acceptance and growth
- None.
Insights
The introduction of FemaSeed as a novel infertility treatment option marks a significant advancement in reproductive medicine. This technology's ability to deliver sperm directly to the fallopian tube could potentially increase fertilization rates compared to traditional intrauterine insemination (IUI). The reported higher success rates in clinical trials are particularly noteworthy.
However, it's important to note that while promising, more extensive real-world data will be necessary to fully validate FemaSeed's efficacy across diverse patient populations. The cost-effectiveness of FemaSeed compared to IVF could make it an attractive first-line treatment, potentially expanding the market for fertility services. This could positively impact Femasys's revenue streams if adoption rates meet expectations.
The onboarding of key infertility clinics in California and Florida represents a strategic market entry for Femasys. These partnerships could serve as important reference points for further expansion. However, investors should note that the revenue impact may be gradual, depending on adoption rates and reimbursement policies.
The cost-effectiveness of FemaSeed compared to IVF could be a significant market driver, potentially expanding Femasys's addressable market. This could lead to increased revenue and market share in the fertility sector. However, the company's ability to scale operations and maintain margins as demand grows will be critical. Investors should monitor clinic adoption rates and patient feedback in the coming quarters to gauge the technology's market traction and potential financial impact.
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
ATLANTA, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces the onboarding of the first infertility medical clinic customers to offer its FemaSeed infertility treatment to patients in California and Florida.
“Femasys has begun partnering with infertility centers across the United States, enabling them to offer FemaSeed to their patients. We are excited to welcome Reproductive Fertility Center and Palm Beach Fertility Center as our first customers,” said Femasys CEO Kathy Lee-Sepsick. “We are enthusiastic about expanding FemaSeed’s availability and anticipate broader acceptance within the medical community as its distinct benefits gain wider recognition.”
FemaSeed is a unique form of artificial insemination because it delivers the sperm directly and safely into the fallopian tube on the side of ovulation. It is intended to enhance natural fertilization and provide a first-line treatment option for those seeking pregnancy. When compared to other reproductive technologies, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), it's a highly cost-effective and affordable procedure that is also safe and well-tolerated by patients.
Dr. Peyman Saadat, Reproductive Fertility Center in Los Angeles, California commented, “We look forward to providing our patients with another fertility treatment option, especially one that may provide benefit over IUI and is affordable for those struggling with financial constraints. We expect there to be growing interest once we begin to educate women about FemaSeed.”
Dr. David Kreiner, Palm Beach Fertility Center in Boca Raton, Florida said, “FemaSeed’s pregnancy success rate in its clinical trial shows a major improvement of this new treatment over traditional IUI using modern technology that can impact women fulfilling their fertility journey. We are thrilled to be at the forefront of providers offering FemaSeed.”
About FemaSeed
FemaSeed® is an innovative advancement in artificial insemination, designed to enhance fertilization by precisely delivering sperm into the fallopian tube, the natural site of conception. It is intended to be a first-line therapeutic choice for infertile women, men, and couples seeking pregnancy through insemination, offering a safe, accessible, and cost-effective approach. FemaSeed is a revolutionary device that allows healthcare professionals an ability to expand practice services with a more affordable and safer alternative to assisted reproductive methods, such as in vitro fertilization (IVF). FemaSeed received U.S. FDA clearance (September 2023) and regulatory approval in Canada (April 2023) and CE mark for Europe (June 2024). At the end of the fourth quarter of 2023, Femasys concluded a prospective, multi-center, unblinded pivotal clinical trial (NCT0468847) for those seeking intratubal insemination with FemaSeed. Adverse events were consistent with intrauterine insemination (IUI). Efficacy analysis focused on male factor (1 million to 20 million TMSC). In this population, pregnancy rate was
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® MINI for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About Reproductive Fertility Center
Under the guidance of Dr. Peyman Saadat, Reproductive Fertility Center continues to offer services to people who may have been turned away from other clinics. Our philosophy is to care for the whole patient, thereby reducing the impact that your treatment has on your everyday life. RFC offers comprehensive fertility treatments for both men and women, including IVF, egg donor cycles, surrogacy options, fertility preservation and more. Contact us at: 310.881.8846; www.reproductivefertility.com
About Palm Beach Fertility Center
At Palm Beach Fertility Center, we provide individualized attention combined with state-of-the-art technology. Patients can rest assured they have access to the most advanced fertility treatments in our warm, supportive atmosphere. That’s why we continue to be a leader in providing top-tier fertility treatment services to patients not just from all over Florida, but across the globe, too. Numerous advances in clinical treatment and laboratory protocols have enabled us to maintain our high pregnancy rates and continue our quest to improve the quality of fertility treatment. Contact us at: 888.819.5177; www.palmbeachfertility.com
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasys.com
Media Contact:
Kati Waldenburg
Media@femasys.com
FAQ
What is FemaSeed and how does it differ from traditional fertility treatments?
Which clinics are the first to offer Femasys' (FEMY) FemaSeed treatment?
What are the potential advantages of FemaSeed according to Femasys (FEMY)?
How does Femasys (FEMY) plan to expand the availability of FemaSeed?
